Publications, videos, and educational content about our AI-driven drug discovery platform
Independent validation of AI-designed antibodies with up to 269× affinity improvement. Peer-reviewed publication demonstrating platform capabilities.
Read Full Paper →Our platform predicted variant escape mutations months before clinical appearance, demonstrating predictive power for pandemic response.
IL-13 × TSLP bispecific antibody designed by Sentinus.AI platform now in Phase I clinical trials for respiratory diseases.
Understanding computational approaches to de novo antibody design without animal immunization
From target identification to clinical trials — where AI accelerates the process
Why 60%+ of new drug approvals now require companion diagnostics
Sentinus.AI-designed bispecific antibody enters human dosing in respiratory disease trial.
Awarded for pandemic preparedness and breakthrough infectious disease work.
Partnerships with Pfizer, Bayer, Yale, Weill Cornell, and leading biotechs.